FDA Approves Biogen’s Drug for Rare Form of ALS

The New York Times - Business:

The drug, which will be sold as Qalsody by the pharmaceutical company Biogen, targets a genetic cause of a devastating neurological illness.

Author: Rebecca Robbins

This post first appeared in The New York Times - Business. Read the original article.